Zhengxiao Ouyang
Qianli Huang
Bin Liu
Hong Wu
Tang Liu
Yong Liu1*- 1State Key Laboratory of Powder Metallurgy, Central South University, Changsha, China
- 2Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China
A Correction on
Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis
by Ouyang Z, Huang Q, Liu B, Wu H, Liu T and Liu Y (2019). Front. Pharmacol. 10:584. doi: 10.3389/fphar.2019.00584
There was a mistake in Figure 1B as published. Specifically, the image for the control in the BMMs group was incorrectly selected during figure preparation. The affected image has been replaced with the correct representative image from the original experiments.
Figure 1. RbCl attenuates osteoclast formation and function without causing cytotoxicity in vitro. (A) Cell viability of osteoclast precursors after RbCl treatment from 24 to 96 h. (B) In vitro osteoclast formation of primary BMMs and RAW264.7 cells after RANKL and RbCl treatment. (C) Quantification of osteoclastogenesis by RbCl. (D) Formation of F-actin ring and bone resorption pits after RANKL and RbCl treatment. (E) Quantification of F-actin ring and bone resorption pits. *p < 0.05 compared with control. Each experiment was repeated biologically in triplicate independently.
The corrected Figure 1B appears below.
These changes do not affect the scientific conclusions of the article in any way.
The original article has been updated.
Generative AI statement
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: rubidium chloride, osteoclast, osteoblast, MAPK, NF-κB, osteoporosis
Citation: Ouyang Z, Huang Q, Liu B, Wu H, Liu T and Liu Y (2026) Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Front. Pharmacol. 16:1678247. doi: 10.3389/fphar.2025.1678247
Received: 02 August 2025; Accepted: 19 December 2025;
Published: 08 January 2026.
Edited and reviewed by:
Peter Vee Sin Lee, The University of Melbourne, AustraliaCopyright © 2026 Ouyang, Huang, Liu, Wu, Liu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tang Liu, bGl1dGFuZzEyMDRAY3N1LmVkdS5jbg==; Yong Liu, eW9ubGl1QGNzdS5lZHUuY24=